Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Review
. 2020 May;19(5):333-352.
doi: 10.1038/s41573-020-0061-0. Epub 2020 Mar 4.

Therapeutic strategies for thrombosis: new targets and approaches

Nigel Mackman  1 , Wolfgang Bergmeier  2 , George A Stouffer  3 , Jeffrey I Weitz  4
Affiliations
Review

Therapeutic strategies for thrombosis: new targets and approaches

Nigel Mackman et al. Nat Rev Drug Discov. 2020 May.

Abstract

Antiplatelet agents and anticoagulants are a mainstay for the prevention and treatment of thrombosis. However, despite advances in antithrombotic therapy, a fundamental challenge is the side effect of bleeding. Improved understanding of the mechanisms of haemostasis and thrombosis has revealed new targets for attenuating thrombosis with the potential for less bleeding, including glycoprotein VI on platelets and factor XIa of the coagulation system. The efficacy and safety of new agents are currently being evaluated in phase III trials. This Review provides an overview of haemostasis and thrombosis, details the current landscape of antithrombotic agents, addresses challenges with preventing thromboembolic events in patients at high risk and describes the emerging therapeutic strategies that may break the inexorable link between antithrombotic therapy and bleeding risk.

PubMed Disclaimer

References

    1. Wendelboe, A. M. & Raskob, G. E. Global burden of thrombosis: epidemiologic aspects. Circ. Res. 118, 1340–1347 (2016).
    1. Prandoni, P. Venous and arterial thrombosis: two aspects of the same disease? Eur. J. Intern. Med. 20, 660–661 (2009).
    1. Prandoni, P. et al. Venous thromboembolism and the risk of subsequent symptomatic atherosclerosis. J. Thromb. Haemost. 4, 1891–1896 (2006).
    1. Reich, L. M. et al. Prospective study of subclinical atherosclerosis as a risk factor for venous thromboembolism. J. Thromb. Haemost. 4, 1909–1913 (2006).
    1. Braekkan, S. K. et al. Family history of myocardial infarction is an independent risk factor for venous thromboembolism: the Tromso study. J. Thromb. Haemost. 6, 1851–1857 (2008).

MeSH terms

LinkOut - more resources